REVIEW Landiolol acts as a highly cardioselective, ultra-short-acting beta blocker used as an anti-arrhythmic agent. It was developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. It is approximately nine times more potent in beta-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. It has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease.
Iguchi, Yoichi; Wakatsuka, Hirohisa Preparation of (2,2-dimethyl-1,3-dioxolan-4S-yl)methyl 3-[4-(2S-hydroxy-3-(2-morpholinocarbonylaminoethyl)aminopropoxyphenyl]propionate hydrochloride as beta1-adrenergic antagonist and its intermediate Jpn. Kokai Tokkyo Koho (1993), JP 05306281 A 19931119.
Iguchi, Sadahiko; Iwamura, Hiroyuki; Nishizaki, Minoru; Hayashi, Akio; Senokuchi, Kazuhiko; Kobayashi, Kaoru; Sakaki, Katsuhito; Hachiya, Katsutoshi; Ichioka, Yumiko; Kawamura, Masanori Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101 Chemical & Pharmaceutical Bulletin (1992), 40(6), 1462-9.
Yoshiya I.Landiolol hydrochloride, a new sympathetic beta blocker. Masui. 1998 Dec;47 Suppl:S126-32.
Ogata J, Okamoto T, Minami K.Landiolol for the treatment of tachyarrhythmia associated with atrial fibrillation. Can J Anaesth. 2003 Aug-Sep;50(7):753.